Harvard Bioscience Q4 Revenue Tops Guidance at $23.7M, EBITDA Up 27%
Harvard Bioscience reported preliminary fourth quarter revenue of $23.7 million, above guidance midpoint, with a 60% gross margin at the top of its range and adjusted EBITDA of $3.8 million, up 27% year-over-year. The company expects mid- to high-single-digit adjusted EBITDA growth and revenue increases in 2026.
1. Preliminary Fourth Quarter Results
Harvard Bioscience reported preliminary fourth quarter 2025 revenue of $23.7 million, exceeding the midpoint of its $22.5–$24.5 million guidance range. Gross margin reached 60%, the high end of guidance, and adjusted EBITDA rose 27% year-over-year to $3.8 million, driven by cost reductions and improved product mix.
2. 2026 Financial Outlook
The company forecasts year-over-year revenue growth and mid- to high-single-digit adjusted EBITDA growth in 2026, supported by a stronger balance sheet following debt refinancing and ongoing operational improvements.
3. Long-Term Strategic Focus Areas
Harvard Bioscience’s strategy focuses on bridging in vitro and in vivo research by expanding into organoid and 3D biology markets, accelerating high-margin product introductions such as SoHo™ telemetry and MeshMEA, growing recurring consumables and software revenues from 55%, and enhancing operational efficiency through U.S. manufacturing consolidation.